HIK.L vs JAZZ
HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets. JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for patients with complex sleep disorders and challenging oncology conditions.
Side-by-side fundamentals
| Metric | HIK.L | JAZZ | Edge |
|---|---|---|---|
| Price | £16.46 | $222.45 | |
| Market cap | $4.5B | $14.4B | |
| P/E as of 2026-10-08 | n/a | 15.21 | |
| Net margin | +12.2% | -8.3% | HIK.L higher |
| Gross margin FY to 2025-12-31, filed 2026-03-18 | +43.0% | n/a | |
| Operating margin FY2025, SEC XBRL | n/a | -10.1% | |
| ROE | +15.6% | -8.2% | HIK.L higher |
| ROA FY2025, SEC XBRL | n/a | -3.1% | |
| Debt / equity as of 2026-09-02 | n/a | 0.91 | |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +12.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-02 | n/a | 0.75 | |
| 1-year return | -9.8% | +61.5% | JAZZ higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.